|
| |
| | | 63023 | | 27.03.2014 | | Takeda Pharma AG | | | | | | | | | | | | | 01.10.20. | | | | 01.10.20. | | IPro |
| | Seq.-nr. | Préparation | Description | Forme galénique | Classe d'ATC | |
|---|
| 01 | Elvanse 30 mg | Hartkapseln | Capsules (Lisdexamfetamini Dimesilas 30 mg) | N06BA12 | IPat | | 02 | Elvanse 50 mg | Hartkapseln | Capsules (Lisdexamfetamini Dimesilas 50 mg) | N06BA12 | IPat | | 03 | Elvanse 70 mg | Hartkapseln | Capsules (Lisdexamfetamini Dimesilas 70 mg) | N06BA12 | IPat | | 04 | Elvanse 20 mg | Hartkapseln | Capsules (Lisdexamfetamini Dimesilas 20 mg) | N06BA12 | IPat | | 05 | Elvanse 40 mg | Hartkapseln | Capsules (Lisdexamfetamini Dimesilas 40 mg) | N06BA12 | IPat | | 06 | Elvanse 60 mg | Hartkapseln | Capsules (Lisdexamfetamini Dimesilas 60 mg) | N06BA12 | IPat |
|
|
|
